A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum-resistant ovarian cancer (OC).

J Voortman

doi:https://doi.org/10.1200/jco.2014.32.15_suppl.2529

A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum-resistant ovarian cancer (OC).

Research output: Contribution to conference › Poster › Academic

Original language	English
DOIs	https://doi.org/10.1200/jco.2014.32.15_suppl.2529
Publication status	Published - 2014
Event	ASCO 2014 - Duration: 1 Jun 2014 → …

Conference

Conference	ASCO 2014
Period	1/06/2014 → …

Access to Document

https://doi.org/10.1200/jco.2014.32.15_suppl.2529

Cite this

@conference{c35f83bbf47447d3af3f759136bf0d4b,

title = "A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum-resistant ovarian cancer (OC).",

author = "J Voortman",

year = "2014",

doi = "https://doi.org/10.1200/jco.2014.32.15_suppl.2529",

language = "English",

note = "ASCO 2014 ; Conference date: 01-06-2014",

}

TY - CONF

T1 - A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum-resistant ovarian cancer (OC).

AU - Voortman, J

PY - 2014

Y1 - 2014

U2 - https://doi.org/10.1200/jco.2014.32.15_suppl.2529

DO - https://doi.org/10.1200/jco.2014.32.15_suppl.2529

M3 - Poster

T2 - ASCO 2014

Y2 - 1 June 2014

ER -